Despite heightened efforts to improve and some significant progress, clinical trials still have a long way to go to reach the goal of diversity, equity and inclusion (DE&I), say FDA Oncology Center of Excellence (OCE) officials, sponsors and the American Association for Cancer Research (AACR), in a new report outlining diversity practices being used in oncology trials.